Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped evolving standard of care and difficulties of enrolling participants

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Eribulin mesylate
DRUG: Eribulin mesylate
DRUG: Eribulin mesylate
OTHER: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)
OTHER: Biologic: PEGylated recombinant human hyaluronidase

Sponsor

Eisai Inc.

Collaborators

[object Object]